Next Article in Journal
Comparative Study of the Molecular Basis of Pathogenicity of M. bovis Strains in a Mouse Model
Previous Article in Journal
Diet-Independent Correlations between Bacteria and Dysfunction of Gut, Adipose Tissue, and Liver: A Comprehensive Microbiota Analysis in Feces and Mucosa of the Ileum and Colon in Obese Mice with NAFLD
Previous Article in Special Issue
Dissection of the Structural Features of a Fungicidal Antibody-Derived Peptide
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 20
Issue 1
10.3390/ijms20010002
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification and In Vivo Characterisation of Cardioactive Peptides in Drosophila melanogaster

by
Ronja Schiemann
,
Kay Lammers
,
Maren Janz
,
Jana Lohmann
,
Achim Paululat
and
Heiko Meyer
*
Department of Zoology and Developmental Biology, University of Osnabrück, Barbarastraße 11, 49076 Osnabrück, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(1), 2; https://doi.org/10.3390/ijms20010002
Submission received: 2 November 2018 / Accepted: 22 November 2018 / Published: 20 December 2018
(This article belongs to the Special Issue Peptides for Health Benefits)
Browse Figures
Versions Notes

Abstract

:
Neuropeptides and peptide hormones serve as critical regulators of numerous biological processes, including development, growth, reproduction, physiology, and behaviour. In mammals, peptidergic regulatory systems are complex and often involve multiple peptides that act at different levels and relay to different receptors. To improve the mechanistic understanding of such complex systems, invertebrate models in which evolutionarily conserved peptides and receptors regulate similar biological processes but in a less complex manner have emerged as highly valuable. Drosophila melanogaster represents a favoured model for the characterisation of novel peptidergic signalling events and for evaluating the relevance of those events in vivo. In the present study, we analysed a set of neuropeptides and peptide hormones for their ability to modulate cardiac function in semi-intact larval Drosophila melanogaster. We identified numerous peptides that significantly affected heart parameters such as heart rate, systolic and diastolic interval, rhythmicity, and contractility. Thus, peptidergic regulation of the Drosophila heart is not restricted to chronotropic adaptation but also includes inotropic modulation. By specifically interfering with the expression of corresponding peptides in transgenic animals, we assessed the in vivo relevance of the respective peptidergic regulation. Based on the functional conservation of certain peptides throughout the animal kingdom, the identified cardiomodulatory activities may be relevant not only to proper heart function in Drosophila, but also to corresponding processes in vertebrates, including humans.

1. Introduction

Peptide signalling represents an evolutionarily highly conserved mechanism for regulating numerous biological processes, including development, growth, reproduction, physiology, and behaviour [1,2,3,4,5,6]. Sessile animals with limited locomotory activities, such as Hydra, utilise distinct neuropeptides, e.g., for signal transmission between neurons and muscles [7,8,9,10]. More evolved animals, such as mammals, exhibit highly complex peptidergic signalling that is still far from being completely understood. The observations that most neuropeptides studied to date fulfil more than one function and that multiple neuropeptides must work in concert to coordinate certain physiological processes render the system extremely diverse [11]. Additionally, the recent and still ongoing identification of small open reading frames (sORFs/smORFs) present in RNAs, which were previously considered noncoding, has contributed to an increasingly complex picture, as many of these ORFs are translated into previously unknown peptides of crucial physiological functionality [12,13,14,15]. Nevertheless, in the last decades, considerable progress has been made toward understanding distinct peptidergic signalling systems [16,17,18]. In this context, invertebrate models have proven highly valuable for understanding the physiological bases of neuropeptide functionality in detail. Crustaceans and insects were commonly used to isolate biologically active peptide species and to measure their respective functionalities via specialised in vitro analyses [19,20,21,22,23,24,25]. More recently, the ability to specifically interfere with expression of peptide precursors or with the expression of the respective receptors has rendered Drosophila melanogaster a favoured organism for studying neuropeptide and peptide hormone function in vivo [26,27,28,29,30]. Corresponding analyses resulted in the identification of numerous mature neuropeptides that are released from individual neurohemal release sites of the Drosophila central nervous system [31,32,33]. In addition, a number of physiological and behavioural aspects were identified as being regulated, at least in part, by peptide signalling in Drosophila. These aspects include reproduction and growth [34,35,36,37,38], food intake [39,40,41], learning and memory [42,43,44], and circadian rhythmicity [45,46,47,48,49].
Despite its physiological significance, very little is known about the peptidergic regulation of the Drosophila heart. In former studies, we characterised the substrate specificity of Neprilysin 4 (Nep4), a heart surface bound metallopeptidase [40,50]. In the course of these investigations, we identified several peptides that were hydrolysed by Nep4 and considered cleavage by the heart bound peptidase initial indication for a putative heart modulatory function of the respective peptide. To assess the validity of this indication, in the present study, we analysed corresponding peptides for cardiomodulatory activity. Presence of the respective neuropeptides and peptide hormones in Drosophila has been experimentally confirmed previously [32,33,51,52,53]. As a result, we identified a number of peptides that significantly modulated heart function in semi-intact animals. Affected parameters included heart rate, systolic and diastolic interval, fractional shortening, and rhythmicity. By specifically interfering with the expression of the peptides´ precursor genes, we further assessed the in vivo relevance of distinct peptides. Thus, our results contribute to an in-depth understanding of the physiological mechanisms that regulate heart function in Drosophila. Considering the functional conservation of certain peptides and receptors, the observed cardiomodulatory activities may also be relevant to corresponding processes in vertebrates, including humans.

2. Results

2.1. The Larval Drosophila Heart Is Highly Responsive to Peptide Application

In previous studies, peptides such as Angiotensin [54], CCAP [55,56], FMRFamide-related peptides [57,58], and Proctolin [59,60,61] were identified as efficient regulators of heart function in Drosophila. To identify additional cardiomodulatory peptides, we analysed a set of neuropeptides and peptide hormones for their ability to modulate distinct larval heart parameters. The presence of all respective peptides in Drosophila, as well as their corresponding molecular masses and sequences, was experimentally confirmed in previous studies [32,33,51,52,53]. In an initial screen, we individually applied each synthesised peptide species at a concentration of 1 × 10−7 M onto semi-intact larval heart preparations and measured the resulting effects on characteristic heart parameters such as heart rate, systolic and diastolic interval, fractional shortening, and rhythmicity via semi-automatic optical heartbeat analysis (SOHA [62]). The tested peptides were Adipokinetic hormone (AKH); Allatostatin A1, A2, A3, and A4 (AstA1–A4); Corazonin; Diuretic hormone 31 (DH31); Drosulfakinins 1 and 2 (DSK1, DSK2); Leucokinin; Proctolin; short Neuropeptide F (sNPF11–11, sNPF212–19); and Tachykinin 1 to 6 (Table 1).
As depicted in Figure 1, six peptides exhibited considerable cardioacceleratory activity. These were Corazonin (+28.1% heart rate increase), DH31 (+40.8% heart rate increase), Proctolin (+48.4% heart rate increase), Tachykinin 1 (+28.8% heart rate increase), Tachykinin 3 (+12.9% heart rate increase), and Tachykinin 5 (+32.6% heart rate increase). None of the tested peptides significantly reduced heart rate. Application of Allatostatin A4 resulted in a complete, yet reversible, heartbeat arrest.
To further specify these results, we performed dose–response experiments with the six identified cardioacceleratory peptides as well as with Allatostatin A4. Applied peptide concentrations were 1 × 10−11 M, 1 × 10−9 M, 1 × 10−7 M, and 1 × 10−5 M. As depicted (Figure 2), most peptides progressively stimulated heart rate while their concentrations were increased from 1 × 10−11 M to 1 × 10−7 M. Only Proctolin and Tachykinin 5 required higher threshold concentrations to induce an effect (1 × 10−7 M). Except for AstA4, all peptides tested exhibited the strongest cardioacceleratory effect at 1 × 10-7 M, with a further increase in concentration resulting in a diminished response. Interestingly, AstA4 induced heartbeat arrest at this particular concentration (1 × 10−7 M), while 1 × 10−9 M and 1 × 10−5 M increased heart rate by 25.7% and 38.4%, respectively. In contrast to all other peptides, Tachykinin 3 decreased heart rate by 14% if applied at 1 × 10−11 M, while higher concentrations (1 × 10−7 M) elicited a cardioacceleratory response (+12.9% increased heart rate).
To assess whether the cardioacceleratory effects were caused by a decreased diastolic or systolic interval, we also measured these parameters individually. Due to the fact that for most peptides the strongest effects on heart rate were recorded at a concentration of 1 × 10−7 M (Figure 2), in this set of experiments, only this concentration was applied. Among the six cardioacceleratory peptides, five significantly reduced the diastolic interval: Corazonin (−21.6%), DH31 (−22.0%), Proctolin (−51.6%), Tachykinin 1 (−31.2%), and Tachykinin 5 (−26.2%) (Figure 3A). By contrast, the systolic interval was affected only by Corazonin (elongated by 13.3%) and DH31 (shortened by 16.4%) (Figure 3B). Thus, the increased heart rates are predominantly caused by decreased diastolic intervals. Interestingly, application of Allatostatin A2 resulted in a shortened diastolic interval (−16.5%), but an elongated systolic interval (+17.2%). In combination, these opposing effects cancelled each other, resulting in an unaltered heart rate (Figure 1 and Figure 3A,B).
To assess possible effects on cardiac muscle contraction, we measured peptide-induced changes in fractional shortening. As depicted in Figure 3C, Leucokinin increased contractility by 11.4 % and Allatostatin A1 increased it by 6.2%. As a final testing parameter, we measured possible peptidergic effects on heart rhythmicity. While application of Proctolin (+197.4%), Tachykinin 1 (+170.2%), and Tachykinin 4 (+152.5%) resulted in significantly increased arrhythmia, none of the remaining peptides affected this parameter in a statistically significant manner (Figure 3D).
The peptide-specific cardiomodulatory effects are summarised in Table 1. Corresponding raw data are presented in Table S1. Representative M-modes for the peptides that significantly affected heart rate are shown in Figure 4.

2.2. Peptidergic Signalling Affects Proper Heart Function In Vivo

As described above, 9 of the 19 peptides tested exhibited a significant modulation of chronotropic heart parameters in semi-intact animals (Allatostatin A2 and A4, Corazonin, DH31, Proctolin, and Tachykinin 1, 3, 4, and 5; Figure 1, Figure 2, Figure 3 and Figure 4 and Table 1). To analyse the physiological relevance of these effects in vivo, we utilised an RNAi mediated knockdown approach, with the aim of reducing abundance of the respective peptide precursor proteins. Ubiquitous daughterless-Gal4 was used to drive RNAi expression in any tissue possibly producing and secreting the peptide of interest. To allow for discrete evaluation of the knockdown effects in vivo, we analysed intact 3rd instar larvae rather than using semi-intact preparations. Of note, due to technical restrictions regarding the reproducible measurement of the heart perimeter in intact animals, which requires a direct view of the tissue without refractive epidermal cells in the optical path, the in vivo analysis was limited to measuring heart rate and rhythmicity. To account for possible off-target effects or variable knockdown efficiencies, we analysed at least two independent RNAi lines per gene. All lines were pre-selected for the expression of individual hairpin sequences. Significant effects were considered valid only if they resulted from two transcript-specific hairpins. As depicted in Figure 5, ubiquitous knockdown of the selected precursor proteins caused discrete effects. Considering the validity criteria depicted above, reduced production of the Allatostatin A, Corazonin, Proctolin, and Tachykinin precursor proteins resulted in a significantly increased heart rate. By contrast, expression of one hairpin specific to the DH31 precursor transcript reduced heart rate, while the second hairpin did not elicit any significant effects (Figure 5A). Regarding heart rhythmicity, knockdown of the Corazonin, DH31, and Tachykinin precursor proteins resulted in a tendency towards a more regular heartbeat. However, in all cases, only one of the analysed hairpins caused statistically significant effects, rendering the analysis of this parameter inconclusive (Figure 5B).
To allow for a detailed evaluation of the knockdown effects, raw data for all lines tested are provided in Table S2.

3. Discussion

Peptidergic signalling represents an evolutionarily highly conserved means of regulating numerous fundamental biological processes. While peptidergic regulation of development, growth, reproduction, and behaviour has been investigated extensively, few studies to date have looked at peptide-based modulation of cardiac function. However, peptide-mediated effects on heart rate and heart contraction have repetitively been identified in Drosophila [54,57,58,59,60,61], with the corresponding peptides acting via distinct G protein-coupled receptors (GPCRs) that in turn activate specific cellular signal transduction pathways [63]. In addition, several studies report on peptide-mediated regulation of cardiac rhythmicity in humans: Endothelin-1 or Angiotensin II are well-known for their ability to modulate heart rhythmicity [64,65,66,67,68,69]. Furthermore, natriuretic peptides affect cardiac rhythmicity, most likely by regulating SERCA activity via cGMP and PKG mediated phosphorylation of Phospholamban. Impairments in this regulation result in cardiac arrhythmia [70,71]. In the present study, we screened a number of peptides evidentially produced in Drosophila melanogaster for their ability to modulate corresponding heart parameters in 3rd instar larvae. We selected this stage of animal development due to the myogenic nature of the larval heart [72]. Thus, all effects described herein should be either intrinsic to heart or based on endocrine signalling, and do not involve any direct innervation component. Among the 19 peptides tested, 11 significantly modulated larval heart function in semi-intact preparations (Figure 1, Figure 2 and Figure 3 and Table 1). While at first sight this ratio of cardioactive peptides appears to be rather high, it is likely consequential of the fact that we pre-selected the tested peptides and analysed only factors that have previously been identified as substrates of the heart surface bound peptidase Nep4 [40]. Since we consider cleavage by the peptidase indicative of a heart modulatory function, the high proportion of cardioactive peptides becomes more allegeable. In this respect, our results that, except for Tachykinin 3, all identified peptides acted exclusively as positive regulators of chronotropic (Figure 1 and Figure 2) or inotropic heart parameters (Figure 3C) may suggest that the peptidergic regulation of larval heart physiology is largely restricted to augmenting respective parameters, while reduced heart rate/heart contractility is predominantly achieved through the removal of corresponding peptides from the haemolymph. The latter likely involves hydrolysis by certain peptidases present at the surface of muscle or heart cells, such as Nep4 [40,50]. Of note, some of the identified peptides affected multiple cardiac parameters, while others exhibited more functional specificity. For example, Proctolin and Tachykinin 1 modified heart rate and rhythmicity, while Corazonin, DH31, and Tachykinin 5 specifically increased heart rate. By contrast, Tachykinin 4 affected only heart rhythmicity (Figure 1, Figure 2 and Figure 3 and Table 1). Interestingly, the only two peptides that altered fractional shortening, Allatostatin A1 and Leucokinin (Figure 3C), also exclusively modulated this parameter. Considering the fact that vice versa none of the chronotropic peptides affected fractional shortening (Table 1), these observations suggest that activity of cardiomodulatory peptides in general is either specific to chronotropic or to inotropic modulation. In addition, these results indicate a complex peptidergic regulation of the larval Drosophila heart that involves chronotropic and inotropic adaptation and requires simultaneous signalling from several specific factors. With regard to inotropic modulation, we identified Allatostatin A1 and Leucokinin as regulatory peptides. Interestingly, leucokinins have already been associated with muscle contractility and a stimulatory effect of the peptides on hindgut contraction in Leucophaea maderae has been reported [73,74]. The maximum response for each leucokinin species was recorded at 2.1 × 10−7 M; however, the heart did not respond to any of the peptides. By contrast, our data clearly show that Leucokinin increases the contractility of the larval Drosophila heart at comparable concentrations (1 × 10−7 M, Figure 3C). Thus, while the general effect on muscle tissue seems to be conserved, leucokinins apparently exhibit species-dependent tissue specificities, probably based on the presence or absence of a corresponding receptor at the surface of a given tissue.
Regarding Drosophila tachykinins (DTKs), two receptors have been identified: NKD (neurokinin receptor from Drosophila), and DTKR (Drosophila tachykinin receptor). With respect to NKD, it has been shown that it can be activated only by DTK-6 [75]. Since we found that DTK-6 application did not affect cardiac activity (Figure 1 and Figure 3), participation of NKD in the peptidergic regulation of the Drosophila heart appears unlikely. By contrast, DTKR has been reported to be responsive to all six Drosophila tachykinins, with DTK-1 inducing the strongest response (EC50 = 3.9 × 10−9 M) and DTKs -2 to -6 being about one order of magnitude less active [76]. This broader specificity along with our results that numerous Drosophila tachykinins affected heart function (DTK-1, -3, -4, and -5; Figure 1, Figure 2 and Figure 3) indicates that cardiac-specific tachykinin signalling is mainly relayed via DTKR. Interestingly, DTK-2 and DTK-6 did not elicit any significant effect, although they have been reported to activate DTKR expressed in HEK-293 cells [76]. This result indicates that DTK-2 and -6 may have additional functions in Drosophila larvae, probably mediated by binding to a receptor different from NKD or DTKR, which attenuate the effects of DTKR activation in cardiac tissue. Concentration dependent activation of distinct receptors may also be causal to our observation that DTK-3 reduces heart rate at 1 × 10−11 M, but increases the same parameter at 1 × 10−7 M (Figure 2). With respect to allatostatins, a similar situation may be present. Also for these peptides, two receptor proteins have been identified in Drosophila (DAR-1 and DAR-2). According to Ca2+ mobilisation assays in transfected CHO cells, both receptors exhibit EC50 values in the range of 20–100 nM for all allatostatins tested (AstA1–AstA4 [77]). Thus, similar cardiomodulatory effects would be expected for these peptides if DAR-1 and DAR-2 were the only responsive receptors in Drosophila. Interestingly, we observed a significant effect on heart function only in response to AstA2 and AstA4 application, while AstA1 and AstA3 did not affect any chronotropic heart parameter (Figure 1 and Figure 3). This lack of activity observed for two of the four tested allatostatins indicates that neither DAR-1 nor DAR-2 is involved in regulating larval Drosophila heartbeat. Consequently, the distinct effects of AstA2 and AstA4 application are presumably mediated by activation of yet unknown receptors. As confirmed by dose–response experiments, AstA4 mediated activation of such a putative receptor resulted in an increased heart rate at ligand concentrations of 1 × 10−9 M and 1 × 10−5 M (Figure 2). Interestingly, at 1 × 10−7 M a complete, yet reversible heartbeat arrest occurred, indicating an unphysiologically strong response at this particular AstA4 concentration that may result in stress-induced heart failure.
To assess the in vivo relevance of these data in more detail, we analysed the physiological effects of all chronotropic peptides identified in our screen (Allatostatin A2 and A4, Corazonin, DH31, Proctolin, and Tachykinin 1, 3, 4, and 5) in intact transgenic larvae. In this respect, we used ubiquitous RNAi (daughterless-Gal4) to knockdown expression of the respective precursor proteins in any tissue possibly producing and secreting the peptide of interest. As shown in Figure 5, knockdown of all peptide precursors affected heart rate, which substantiates a cardiomodulatory activity of the mature peptides. Interestingly, only DH31 precursor knockdown resulted in a tendency to decrease this parameter, while reduced levels of the Allatostatin, Corazonin, Proctolin, and Tachykinin precursor increased heart rate (Figure 5A). These results are surprising, since our data from semi-intact heart preparations indicate a cardioacceleratory activity of all respective peptides (Figure 1 and Figure 2). Thus, vice versa, knockdown of the respective precursor proteins should result in decreased heart rate. However, given the fact that neuropeptides typically have different roles during development and adulthood, the observed knockdown effects may reflect a combination of physiological and developmental impairments. In addition, knockdown of a precursor protein usually affects numerous mature peptides. This simultaneous loss of peptide signalling, probably interfering with multiple peptidergic systems, may cause considerable physiological stress that is sensed by the heart and results in an increased heart rate. On the other hand, the type of assay may also influence the effects on heart rate. In Cancer magister, it has been shown that different experimental setups can affect the results, as Proctolin application in intact animals decreased heart rate, while semi-isolated hearts exhibited a cardioacceleratory response [78]. At least with respect to Proctolin, this discrepancy is observed also in Drosophila: while Proctolin injection into 3rd instar larvae is reported to decrease heart rate [61], our results using semi-intact animals clearly show a cardioacceleratory activity of the peptide (Figure 1 and Figure 2). Thus, a combination of methodical setups appears to be required to adequately characterise cardioactive peptides in Drosophila. However, considering the reduced complexity and the resulting gain in interpretability, we regard direct application analyses using semi-intact heart preparations as favourable techniques for initial peptide identification.
By combining semi-intact heart preparations with in vivo analyses, we have identified a number of cardioactive peptides in Drosophila melanogaster. While in-depth analyses of the distinct physiological functions of these peptides require further efforts, our data represent a valuable resource for designing corresponding studies in the future.

4. Materials and Methods

4.1. Fly Strains

daughterless-Gal4 (da-Gal4, RRID:BDSC_55850) was used as a ubiquitous driver. RNAi lines (Table 2) were obtained from either the Vienna Drosophila Resource Center (VDRC) or the Bloomington Drosophila Stock Center (BDSC). The KK collection specific host strain VDRC-ID 60101 was used as a control for the KK RNAi lines, and the strain BDSC_36303 served as a control for the TRiP RNAi lines (each of them crossed to da-Gal4). Both control lines share identical genetic backgrounds with the lines of the respective collection (KK or TRiP). The genetically distinct lines of the GD collection (Table 2) were controlled by crossing both, the respective UAS-RNAi lines as well as the applied driver line (da-Gal4) to w1118 (RRID:BDSC_5905).

4.2. Peptide Application Assay and Dose–Response Analysis

Prior to peptide application, wandering male 3rd instar larvae were dissected in artificial haemolymph (5 mM KCl, 8 mM MgCl2, 2 mM CaCl2, 108 mM NaCl, 1 mM NaH2PO4, 5 mM HEPES and 4 mM NaHCO3, pH 7.1). Prior to use, the buffer was supplemented with trehalose (final concentration: 5 mM) and sucrose (final concentration: 10 mM) [79]. Specimens were pinned down with the ventral side upwards onto Sylgard 184 silicone elastomer plates. All internal organs except for the heart and associated tissue (e.g. alary muscles, pericardial cells) were removed. After a resting period of 10 min, a 60 s video of the heartbeat was recorded and used as a control. Afterwards, the artificial haemolymph was removed and replaced with artificial haemolymph containing a candidate peptide (Table 1). After 1 min, the heartbeat was again recorded for 60 s and analysed for peptide-specific alterations in comparison to the respective control measurement. For an initial screen, only one peptide concentration was tested (1 × 10−7 M). To further assess the dose–responsive relationship of positive candidates, three additional concentrations (1 × 10−11 M, 1 × 10−9 M and 1 × 10−5 M) of the respective peptides were applied. All peptides were synthesised by JPT Peptide Technologies (Berlin, Germany) and were of >90 % purity. The proper sequence and mass of each peptide was confirmed using an ESI-ion trap (Amazon ETD Speed with a captive spray ionisation unit, Bruker Corporation, Billerica, MA, USA) by measuring the masses of the intact molecules as well as the masses of the fragments, which were generated by collision-induced dissociation (CID) of the corresponding parent ion.

4.3. In Vivo Measurement of Heart Parameters

To measure the heart function of animals with ubiquitous knockdown of the peptide precursors or cardiac-specific knockdown of their receptors in vivo, wandering male 3rd instar larvae were anaesthetised for 8 min using ether. The anaesthetised animals were transferred with the dorsal side upwards to a moistened microscope slide and a 60 s video of the beating heart was captured through the cuticle. For optimal detection of the heartbeat, the camera was focused on a region in which the heart tube was in close proximity to trachea (dorsal trunks) or fat body tissue, allowing the simultaneous detection of the heartbeat and related movements of the surrounding tissues with high contrast.

4.4. Video Analysis and Calculation of Cardiac Parameters

For heartbeat recording, a high-speed video camera (Basler piA-640) was mounted onto an upright microscope (Leica DMLB) equipped with a 10× Leica Fluotar. Movies were captured with the software Firecapture ® (freeware by Torsten Edelmann) and processed with ImageJ [80].
For the peptide screen, heart parameters were analysed using SOHA (semi-automated optical heartbeat analysis), a MATLAB application introduced by Fink et al. [62] and further developed by Ocorr et al. [81]. The SOHA software utilises two computer algorithms to combine overall darkness changes of a video (Frame Brightness Algorithm) with pixel-by-pixel intensity changes (Changing Pixel Intensity Algorithm), thereby allowing calculation of different heart beat parameters. Besides the heart rate [Hz] and systolic/diastolic intervals (duration of contraction and relaxation phases [ms]), also contractility ([%] of fractional shortening) as well as heart beat arrhythmia can be determined. To measure fractional shortening, the SOHA software allows manually annotating the edges of the heart tube at its maximally dilated and maximally contracted state. Based on these diameters, percentages of fractional shortening can be calculated:
% FS = Diastolic   diameter − Systolic   diameter Diastolic   diameter   × 100
As described in [62], the arrhythmicity index was calculated via dividing the standard deviation of the heart period by the median of the heart period:
AI = Standard   deviation   ( HP ) Median   ( HP )
Additionally, the SOHA software also generates kymographs (M-modes) of heart wall movements (X-axis) over time (Y-axis). M-modes are horizontally aligned pixel slices from each frame of a respective heart beat video. In this way, an M-mode allows visualising distinct differences in heart performance (e.g. heart rate). Additional data analysis was done using Microsoft Excel and GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).
Analysis of in vivo heart parameters was done by measuring the changes in light intensity that occur during a single heartbeat. For automated evaluation of the parameter values, a self-compiled Java script with OpenCV (Open Source Computer Vision, [82]) was employed. The resulting plots (Figure S1) were verified for proper heartbeat detection. Additional data analysis was done using Microsoft Excel.

4.5. Statistics

Statistical analysis was performed using Microsoft Excel. For the peptide screen, a minimum of 10 animals per peptide were measured. Paired sample t-tests were performed to determine the statistical significance of peptide-specific effects. For statistical analysis of in vivo effects, an independent samples t-test was used. At least 10 animals per genotype were analysed.

Supplementary Materials

The following are available online at https://www.mdpi.com/1422-0067/20/1/2/s1, Figure S1: Representative plots of heartbeat detection in intact animals: (A) da-Gal4 x BDSC_60101 (control, KK); and (B) da-Gal4 x BDSC_103215 (KK). Detected heartbeats (black dots) are labelled by consecutive numbers. In contrast to control animals (A), knockdown of the Allatostatin precursor protein results in increased heart rate (B); Table S1: Raw data of peptide-specific cardiomodulatory effects in semi-intact animals; Table S2: Raw data of knockdown-specific cardiomodulatory effects in intact animals.

Author Contributions

H.M., R.S. and A.P. conceived and designed the experiments. R.S., M.J., K.L. and J.L. performed the experiments. H.M., R.S., M.J., K.L., J.L. and A.P. analysed the data. H.M. and A.P. wrote the paper.

Funding

This research was funded by the German Research Foundation (SFB 944: Physiology and Dynamics of Cellular Microcompartments) (A.P.), by a young investigator initiative of the SFB 944 (H.M.), by a stipend from the Hans Mühlenhoff Foundation (R.S.), and by the State of Lower-Saxony, Hannover, Germany, Grant 11-76251- 99-15/12 (ZN2832) (A.P.). We also acknowledge the support of the Open Access Publishing Fund of Osnabrück University.

Acknowledgments

We thank Martina Biedermann, Mechthild Krabusch and Eva Cordes for excellent technical assistance. We also thank Christian Wegener for providing peptides. We further acknowledge the Vienna Drosophila Resource Center (VDRC) and the Bloomington Drosophila Stock Center (BDSC, NIH P40OD018537) for providing fly stocks.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bouwman, J.; Spijker, S.; Schut, D.; Wachtler, B.; Ylstra, B.; Smit, A.B.; Verhage, M. Reduced expression of neuropeptide genes in a genome-wide screen of a secretion-deficient mouse. J. Neurochem. 2006, 99, 84–96. [Google Scholar] [CrossRef] [Green Version]
  2. Hewes, R.S.; Taghert, P.H. Neuropeptides and neuropeptide receptors in the Drosophila melanogaster genome. Genome Res. 2001, 11, 1126–1142. [Google Scholar] [CrossRef] [PubMed]
  3. Hokfelt, T. Neuropeptides in perspective: the last ten years. Neuron 1991, 7, 867–879. [Google Scholar] [CrossRef]
  4. Husson, S.J.; Landuyt, B.; Nys, T.; Baggerman, G.; Boonen, K.; Clynen, E.; Lindemans, M.; Janssen, T.; Schoofs, L. Comparative peptidomics of Caenorhabditis elegans versus C. briggsae by LC-MALDI-TOF MS. Peptides 2009, 30, 449–457. [Google Scholar] [CrossRef]
  5. Li, B.; Predel, R.; Neupert, S.; Hauser, F.; Tanaka, Y.; Cazzamali, G.; Williamson, M.; Arakane, Y.; Verleyen, P.; Schoofs, L.; et al. Genomics, transcriptomics, and peptidomics of neuropeptides and protein hormones in the red flour beetle Tribolium castaneum. Genome Res. 2008, 18, 113–122. [Google Scholar] [CrossRef] [PubMed]
  6. Nässel, D.R.; Winther, A.M. Drosophila neuropeptides in regulation of physiology and behaviour. Prog. Neurobiol. 2010, 92, 42–104. [Google Scholar] [CrossRef]
  7. Anctil, M. Chemical transmission in the sea anemone Nematostella vectensis: A genomic perspective. Comp. Biochem. Physiol. Part D Genom. Proteom. 2009, 4, 268–289. [Google Scholar] [CrossRef]
  8. Grimmelikhuijzen, C.J.; Leviev, I.; Carstensen, K. Peptides in the nervous systems of cnidarians: Structure, function, and biosynthesis. Int. Rev. Cytol. 1996, 167, 37–89. [Google Scholar] [PubMed]
  9. Hansen, G.N.; Williamson, M.; Grimmelikhuijzen, C.J. A new case of neuropeptide coexpression (RGamide and LWamides) in Hydra, found by whole-mount, two-color double-labeling in situ hybridization. Cell Tissue Res. 2002, 308, 157–165. [Google Scholar] [CrossRef]
  10. Takahashi, T.; Hayakawa, E.; Koizumi, O.; Fujisawa, T. Neuropeptides and their functions in Hydra. Acta Boil. Hung. 2008, 59, 227–235. [Google Scholar] [CrossRef]
  11. Schoofs, L.; De Loof, A.; Van Hiel, M.B. Neuropeptides as regulators of behaviour in insects. Annu. Rev. Èntomol. 2017, 62, 35–52. [Google Scholar] [CrossRef] [PubMed]
  12. Anderson, D.M.; Anderson, K.M.; Chang, C.L.; Makarewich, C.A.; Nelson, B.R.; McAnally, J.R.; Kasaragod, P.; Shelton, J.M.; Liou, J.; Bassel-Duby, R.; et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 2015, 160, 595–606. [Google Scholar] [CrossRef] [PubMed]
  13. Anderson, D.M.; Makarewich, C.A.; Anderson, K.M.; Shelton, J.M.; Bezprozvannaya, S.; Bassel-Duby, R.; Olson, E.N. Widespread control of calcium signalling by a family of SERCA-inhibiting micropeptides. Sci. Signal. 2016, 9, ra119. [Google Scholar] [CrossRef] [PubMed]
  14. Nelson, B.R.; Makarewich, C.A.; Anderson, D.M.; Winders, B.R.; Troupes, C.D.; Wu, F.; Reese, A.L.; McAnally, J.R.; Chen, X.; Kavalali, E.T.; et al. A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science 2016, 351, 271–275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Zanet, J.; Chanut-Delalande, H.; Plaza, S.; Payre, F. Small peptides as newcomers in the control of Drosophila development. Curr. Top. Dev. Biol. 2016, 117, 199–219. [Google Scholar] [PubMed]
  16. Baraban, S.C.; Tallent, M.K. Interneuron Diversity series: Interneuronal neuropeptides—Endogenous regulators of neuronal excitability. Trends Neurosci. 2004, 27, 135–142. [Google Scholar] [CrossRef] [PubMed]
  17. Hokfelt, T.; Broberger, C.; Xu, Z.Q.; Sergeyev, V.; Ubink, R.; Diez, M. Neuropeptides—An overview. Neuropharmacology 2000, 39, 1337–1356. [Google Scholar] [CrossRef]
  18. Zupanc, G.K. Peptidergic transmission: From morphological correlates to functional implications. Micron 1996, 27, 35–91. [Google Scholar] [CrossRef]
  19. Keller, R. Crustacean neuropeptides: Structures, functions and comparative aspects. Experientia 1992, 48, 439–448. [Google Scholar] [CrossRef]
  20. Moroz, L.L.; Edwards, J.R.; Puthanveettil, S.V.; Kohn, A.B.; Ha, T.; Heyland, A.; Knudsen, B.; Sahni, A.; Yu, F.; Liu, L.; et al. Neuronal transcriptome of Aplysia: Neuronal compartments and circuitry. Cell 2006, 127, 1453–1467. [Google Scholar] [CrossRef]
  21. Nusbaum, M.P.; Blitz, D.M.; Swensen, A.M.; Wood, D.; Marder, E. The roles of co-transmission in neural network modulation. Trends Neurosci. 2001, 24, 146–154. [Google Scholar] [CrossRef]
  22. O’Shea, M.; Schaffer, M. Neuropeptide function: The invertebrate contribution. Annu. Rev. Neurosci. 1985, 8, 171–198. [Google Scholar] [CrossRef] [PubMed]
  23. Predel, R.; Nachman, R.J.; Gäde, G. Myostimulatory neuropeptides in cockroaches: Structures, distribution, pharmacological activities, and mimetic analogs. J. Insect Physiol. 2001, 47, 311–324. [Google Scholar] [CrossRef]
  24. Predel, R.; Neupert, S.; Garczynski, S.F.; Crim, J.W.; Brown, M.R.; Russell, W.K.; Kahnt, J.; Russell, D.H.; Nachman, R.J. Neuropeptidomics of the mosquito Aedes aegypti. J. Proteome Res. 2010, 9, 2006–2015. [Google Scholar] [CrossRef] [PubMed]
  25. Schoofs, L.; Vanden Broeck, J.; De Loof, A. The myotropic peptides of Locusta migratoria: Structures, distribution, functions and receptors. Insect Biochem. Mol. Biol. 1993, 23, 859–881. [Google Scholar] [CrossRef]
  26. Dietzl, G.; Chen, D.; Schnorrer, F.; Su, K.C.; Barinova, Y.; Fellner, M.; Gasser, B.; Kinsey, K.; Oppel, S.; Scheiblauer, S.; et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 2007, 448, 151–156. [Google Scholar] [CrossRef]
  27. Jones, W.D. The expanding reach of the GAL4/UAS system into the behavioural neurobiology of Drosophila. BMB Rep. 2009, 42, 705–712. [Google Scholar] [CrossRef]
  28. Luo, L.; Callaway, E.M.; Svoboda, K. Genetic dissection of neural circuits. Neuron 2008, 57, 634–660. [Google Scholar] [CrossRef]
  29. McNabb, S.L.; Baker, J.D.; Agapite, J.; Steller, H.; Riddiford, L.M.; Truman, J.W. Disruption of a behavioural sequence by targeted death of peptidergic neurons in Drosophila. Neuron 1997, 19, 813–823. [Google Scholar] [CrossRef]
  30. Pfeiffer, B.D.; Jenett, A.; Hammonds, A.S.; Ngo, T.T.; Misra, S.; Murphy, C.; Scully, A.; Carlson, J.W.; Wan, K.H.; Laverty, T.R.; et al. Tools for neuroanatomy and neurogenetics in Drosophila. Proc. Natl. Acad. Sci. (PNAS) 2008, 105, 9715–9720. [Google Scholar] [CrossRef]
  31. Predel, R.; Eckert, M.; Pollak, E.; Molnar, L.; Scheibner, O.; Neupert, S. Peptidomics of identified neurons demonstrates a highly differentiated expression pattern of FXPRLamides in the neuroendocrine system of an insect. J. Comp. Neurol. 2007, 500, 498–512. [Google Scholar] [CrossRef]
  32. Predel, R.; Wegener, C.; Russell, W.K.; Tichy, S.E.; Russell, D.H.; Nachman, R.J. Peptidomics of CNS-associated neurohemal systems of adult Drosophila melanogaster: A mass spectrometric survey of peptides from individual flies. J. Comp. Neurol. 2004, 474, 379–392. [Google Scholar] [CrossRef] [PubMed]
  33. Wegener, C.; Reinl, T.; Jänsch, L.; Predel, R. Direct mass spectrometric peptide profiling and fragmentation of larval peptide hormone release sites in Drosophila melanogaster reveals tagma-specific peptide expression and differential processing. J. Neurochem. 2006, 96, 1362–1374. [Google Scholar] [CrossRef] [PubMed]
  34. Brogiolo, W.; Stocker, H.; Ikeya, T.; Rintelen, F.; Fernandez, R.; Hafen, E. An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr. Biol. CB 2001, 11, 213–221. [Google Scholar] [CrossRef]
  35. Liu, H.; Kubli, E. Sex-peptide is the molecular basis of the sperm effect in Drosophila melanogaster. Proc. Natl. Acad. Sci. (PNAS) 2003, 100, 9929–9933. [Google Scholar] [CrossRef] [PubMed]
  36. Rulifson, E.J.; Kim, S.K.; Nusse, R. Ablation of insulin-producing neurons in flies: Growth and diabetic phenotypes. Science 2002, 296, 1118–1120. [Google Scholar] [CrossRef] [PubMed]
  37. Wigby, S.; Chapman, T. Sex peptide causes mating costs in female Drosophila melanogaster. Curr. Biol. CB 2005, 15, 316–321. [Google Scholar] [CrossRef]
  38. Yapici, N.; Kim, Y.J.; Ribeiro, C.; Dickson, B.J. A receptor that mediates the post-mating switch in Drosophila reproductive behaviour. Nature 2008, 451, 33–37. [Google Scholar] [CrossRef]
  39. Chen, J.; Reiher, W.; Hermann-Luibl, C.; Sellami, A.; Cognigni, P.; Kondo, S.; Helfrich-Forster, C.; Veenstra, J.A.; Wegener, C. Allatostatin A signalling in Drosophila regulates feeding and sleep and is modulated by PDF. PLoS Genet. 2016, 12, e1006346. [Google Scholar]
  40. Hallier, B.; Schiemann, R.; Cordes, E.; Vitos-Faleato, J.; Walter, S.; Heinisch, J.J.; Malmendal, A.; Paululat, A.; Meyer, H. Drosophila neprilysins control insulin signalling and food intake via cleavage of regulatory peptides. eLife 2016, 5, e19430. [Google Scholar] [CrossRef]
  41. Wang, Y.; Pu, Y.; Shen, P. Neuropeptide-gated perception of appetitive olfactory inputs in Drosophila larvae. Cell Rep. 2013, 3, 820–830. [Google Scholar] [CrossRef] [PubMed]
  42. DeZazzo, J.; Xia, S.; Christensen, J.; Velinzon, K.; Tully, T. Developmental expression of an amn(+) transgene rescues the mutant memory defect of amnesiac adults. J. Neurosci. 1999, 19, 8740–8746. [Google Scholar] [CrossRef] [PubMed]
  43. Feany, M.B.; Quinn, W.G. A neuropeptide gene defined by the Drosophila memory mutant amnesiac. Science 1995, 268, 869–873. [Google Scholar] [CrossRef] [PubMed]
  44. Waddell, S.; Armstrong, J.D.; Kitamoto, T.; Kaiser, K.; Quinn, W.G. The amnesiac gene product is expressed in two neurons in the Drosophila brain that are critical for memory. Cell 2000, 103, 805–813. [Google Scholar] [CrossRef]
  45. Cavey, M.; Collins, B.; Bertet, C.; Blau, J. Circadian rhythms in neuronal activity propagate through output circuits. Nat. Neurosci. 2016, 19, 587–595. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Dubowy, C.M.; Cavanaugh, D.J. Sleep: A neuropeptidergic wake-up call for flies. Curr. Biol. CB 2014, 24, R1092-4. [Google Scholar] [CrossRef] [PubMed]
  47. Hermann-Luibl, C.; Yoshii, T.; Senthilan, P.R.; Dircksen, H.; Helfrich-Forster, C. The ion transport peptide is a new functional clock neuropeptide in the fruit fly Drosophila melanogaster. J. Neurosci. 2014, 34, 9522–9536. [Google Scholar] [CrossRef] [PubMed]
  48. Isaac, R.E.; Johnson, E.C.; Audsley, N.; Shirras, A.D. Metabolic inactivation of the circadian transmitter, pigment dispersing factor (PDF), by neprilysin-like peptidases in Drosophila. J. Exp. Biol. 2007, 210 Pt 24, 4465–4470. [Google Scholar] [CrossRef]
  49. Shang, Y.; Donelson, N.C.; Vecsey, C.G.; Guo, F.; Rosbash, M.; Griffith, L.C. Short neuropeptide F is a sleep-promoting inhibitory modulator. Neuron 2013, 80, 171–183. [Google Scholar] [CrossRef] [PubMed]
  50. Meyer, H.; Panz, M.; Zmojdzian, M.; Jagla, K.; Paululat, A. Neprilysin 4, a novel endopeptidase from Drosophila melanogaster, displays distinct substrate specificities and exceptional solubility states. J. Exp. Biol. 2009, 212 Pt 22, 3673–3683. [Google Scholar] [CrossRef]
  51. Baggerman, G.; Boonen, K.; Verleyen, P.; De Loof, A.; Schoofs, L. Peptidomic analysis of the larval Drosophila melanogaster central nervous system by two-dimensional capillary liquid chromatography quadrupole time-of-flight mass spectrometry. J. Mass Spectrom. 2005, 40, 250–260. [Google Scholar] [CrossRef]
  52. Yew, J.Y.; Wang, Y.; Barteneva, N.; Dikler, S.; Kutz-Naber, K.K.; Li, L.; Kravitz, E.A. Analysis of neuropeptide expression and localisation in adult Drosophila melanogaster central nervous system by affinity cell-capture mass spectrometry. J. Proteome Res. 2009, 8, 1271–1284. [Google Scholar] [CrossRef] [PubMed]
  53. Anderson, M.S.; Halpern, M.E.; Keshishian, H. Identification of the neuropeptide transmitter proctolin in Drosophila larvae: Characterisation of muscle fiber-specific neuromuscular endings. J. Neurosci. 1988, 8, 242–255. [Google Scholar] [CrossRef] [PubMed]
  54. Liao, F.T.; Chang, C.Y.; Su, M.T.; Kuo, W.C. Necessity of angiotensin-converting enzyme-related gene for cardiac functions and longevity of Drosophila melanogaster assessed by optical coherence tomography. J. Biomed. Opt. 2014, 19, 011014. [Google Scholar] [CrossRef] [PubMed]
  55. Dulcis, D.; Levine, R.B.; Ewer, J. Role of the neuropeptide CCAP in Drosophila cardiac function. J. Neurobiol. 2005, 64, 259–274. [Google Scholar] [CrossRef]
  56. Nichols, R.; Kaminski, S.; Walling, E.; Zornik, E. Regulating the activity of a cardioacceleratory peptide. Peptides 1999, 20, 1153–1158. [Google Scholar] [CrossRef]
  57. Johnson, E.; Ringo, J.; Dowse, H. Native and heterologous neuropeptides are cardioactive in Drosophila melanogaster. J. Insect Physiol. 2000, 46, 1229–1236. [Google Scholar] [CrossRef]
  58. Nichols, R.; McCormick, J.; Cohen, M.; Howe, E.; Jean, C.; Paisley, K.; Rosario, C. Differential processing of neuropeptides influences Drosophila heart rate. J. Neurogenet. 1999, 13, 89–104. [Google Scholar] [CrossRef]
  59. Ormerod, K.G.; LePine, O.K.; Bhutta, M.S.; Jung, J.; Tattersall, G.J.; Mercier, A.J. Characterizing the physiological and behavioural roles of proctolin in Drosophila melanogaster. J. Neurophysiol. 2016, 115, 568–580. [Google Scholar] [CrossRef]
  60. Taylor, C.A.; Winther, A.M.; Siviter, R.J.; Shirras, A.D.; Isaac, R.E.; Nässel, D.R. Identification of a proctolin preprohormone gene (Proct) of Drosophila melanogaster: Expression and predicted prohormone processing. J. Neurobiol. 2004, 58, 379–391. [Google Scholar] [CrossRef]
  61. Zornik, E.; Paisley, K.; Nichols, R. Neural transmitters and a peptide modulate Drosophila heart rate. Peptides 1999, 20, 45–51. [Google Scholar] [CrossRef]
  62. Fink, M.; Callol-Massot, C.; Chu, A.; Ruiz-Lozano, P.; Izpisua Belmonte, J.C.; Giles, W.; Bodmer, R.; Ocorr, K. A new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish, and embryonic mouse hearts. BioTechniques 2009, 46, 101–113. [Google Scholar] [CrossRef] [PubMed]
  63. Capote, L.A.; Mendez Perez, R.; Lymperopoulos, A. GPCR signaling and cardiac function. Eur. J. Pharmacol. 2015, 763, 143–148. [Google Scholar] [CrossRef] [PubMed]
  64. Becker, R.; Merkely, B.; Bauer, A.; Geller, L.; Fazekas, L.; Freigang, K.D.; Voss, F.; Senges, J.C.; Kuebler, W.; Schoels, W. Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: A comparative analysis using three-dimensional mapping. Cardiovasc. Res. 2000, 45, 310–320. [Google Scholar] [CrossRef]
  65. Garg, S.; Narula, J.; Marelli, C.; Cesario, D. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias. Am. J. Cardiol. 2006, 97, 921–925. [Google Scholar] [CrossRef] [PubMed]
  66. Gondo, N.; Kumagai, K.; Nakashima, H.; Saku, K. Angiotensin II provokes cesium-induced ventricular tachyarrhythmias. Cardiovasc. Res. 2001, 49, 381–390. [Google Scholar] [CrossRef] [Green Version]
  67. Reid, A.C.; Brazin, J.A.; Morrey, C.; Silver, R.B.; Levi, R. Targeting cardiac mast cells: Pharmacological modulation of the local renin-angiotensin system. Curr. Pharm. Des. 2011, 17, 3744–3752. [Google Scholar] [CrossRef] [PubMed]
  68. Von Lewinski, D.; Kockskämper, J.; Rübertus, S.U.; Zhu, D.; Schmitto, J.D.; Schöndube, F.A.; Hasenfuss, G.; Pieske, B. Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur. J. Heart Fail. 2008, 10, 1172–1176. [Google Scholar] [CrossRef]
  69. Yahiro, E.; Ideishi, M.; Wang, L.X.; Urata, H.; Kumagai, K.; Arakawa, K.; Saku, K. Reperfusion-induced arrhythmias are suppressed by inhibition of the angiotensin II type 1 receptor. Cardiology 2003, 99, 61–67. [Google Scholar] [CrossRef]
  70. Takata, Y.; Hirayama, Y.; Kiyomi, S.; Ogawa, T.; Iga, K.; Ishii, T.; Nagai, Y.; Ibukiyama, C. The beneficial effects of atrial natriuretic peptide on arrhythmias and myocardial high-energy phosphates after reperfusion. Cardiovasc. Res. 1996, 32, 286–293. [Google Scholar] [CrossRef] [Green Version]
  71. Zois, N.E.; Bartels, E.D.; Hunter, I.; Kousholt, B.S.; Olsen, L.H.; Goetze, J.P. Natriuretic peptides in cardiometabolic regulation and disease. Nat. Rev. Cardiol. 2014, 11, 403–412. [Google Scholar] [CrossRef] [PubMed]
  72. Dulcis, D.; Levine, R.B. Innervation of the heart of the adult fruit fly, Drosophila melanogaster. J. Comp. Neurol. 2003, 465, 560–578. [Google Scholar] [CrossRef]
  73. Cook, B.J.; Holman, G.M.; Wagner, R.M.; Nachman, R.J. Pharmacological actions of a new class of neuropeptides, the Leucokinins-I-IV, on the visceral muscles of Leucophaea maderae. Comp. Biochem. Physiol. C 1989, 93, 257–262. [Google Scholar] [CrossRef]
  74. Cook, B.J.; Holman, G.M.; Wagner, R.M.; Nachman, R.J. Comparative pharmacological actions of Leucokinins-V-VIII on the visceral muscles of Leucophaea maderae. Comp. Biochem. Physiol. C 1990, 95, 19–24. [Google Scholar] [CrossRef]
  75. Poels, J.; Birse, R.T.; Nachman, R.J.; Fichna, J.; Janecka, A.; Vanden Broeck, J.; Nässel, D.R. Characterization and distribution of NKD, a receptor for Drosophila tachykinin-related peptide 6. Peptides 2009, 30, 545–556. [Google Scholar] [CrossRef] [PubMed]
  76. Birse, R.T.; Johnson, E.C.; Taghert, P.H.; Nässel, D.R. Widely distributed Drosophila G-protein-coupled receptor (CG7887) is activated by endogenous tachykinin-related peptides. J. Neurobiol. 2006, 66, 33–46. [Google Scholar] [CrossRef] [PubMed]
  77. Larsen, M.J.; Burton, K.J.; Zantello, M.R.; Smith, V.G.; Lowery, D.L.; Kubiak, T.M. Type A allatostatins from Drosophila melanogaster and Diplotera puncata activate two Drosophila allatostatin receptors, DAR-1 and DAR-2, expressed in CHO cells. Biochem. Biophys. Res. Commun. 2001, 286, 895–901. [Google Scholar] [CrossRef]
  78. McGaw, I.J.; Wilkens, J.L.; McMahon, B.R.; Airriess, C.N. Crustacean cardioexcitatory peptides may inhibit the heart in vivo. J. Exp. Biol. 1995, 198 Pt 12, 2547–2550. [Google Scholar]
  79. Vogler, G.; Ocorr, K. Visualizing the beating heart in Drosophila. J. Vis. Exp. 2009. [Google Scholar] [CrossRef]
  80. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef] [Green Version]
  81. Ocorr, K.; Vogler, G.; Bodmer, R. Methods to assess Drosophila heart development, function and aging. Methods 2014, 68, 265–272. [Google Scholar] [CrossRef] [PubMed]
  82. Bradski, G. The OpenCV library. Dr. Dobbs J. 2000, 120, 122–125. [Google Scholar]
Ijms 20 00002 g001 550
Figure 1. Heart rate is modulated by peptide signalling in semi-intact Drosophila larvae. Individual effects of the tested peptides (1 × 10−7 M) on heart rate. Data are presented as mean values (± S.E.M.) of the relative changes in heart rate in relation to the individual control preparations (prior to peptide application). A minimum of ten animals per peptide were measured. Significance levels are indicated by asterisks (paired sample Student´s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001). Application of Allatostatin A4 resulted in a complete heartbeat arrest (heart rate not determined, n.d.).
Figure 1. Heart rate is modulated by peptide signalling in semi-intact Drosophila larvae. Individual effects of the tested peptides (1 × 10−7 M) on heart rate. Data are presented as mean values (± S.E.M.) of the relative changes in heart rate in relation to the individual control preparations (prior to peptide application). A minimum of ten animals per peptide were measured. Significance levels are indicated by asterisks (paired sample Student´s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001). Application of Allatostatin A4 resulted in a complete heartbeat arrest (heart rate not determined, n.d.).
Ijms 20 00002 g001
Ijms 20 00002 g002 550
Figure 2. Dose–response curves for the effects of chronotropic peptides in semi-intact Drosophila larvae. Individual effects of the tested peptides at 1 × 10−11 M, 1 × 10−9 M, 1 × 10−7 M, and 1 × 10−5 M are shown. Data are presented as mean values (± S.E.M.) of the relative changes in heart rate in relation to the individual control preparations (prior to peptide application). A minimum of ten animals per peptide were measured. Significance levels are indicated by asterisks (paired sample Student´s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001). n.d. indicates “not determined” (due to heartbeat arrest).
Figure 2. Dose–response curves for the effects of chronotropic peptides in semi-intact Drosophila larvae. Individual effects of the tested peptides at 1 × 10−11 M, 1 × 10−9 M, 1 × 10−7 M, and 1 × 10−5 M are shown. Data are presented as mean values (± S.E.M.) of the relative changes in heart rate in relation to the individual control preparations (prior to peptide application). A minimum of ten animals per peptide were measured. Significance levels are indicated by asterisks (paired sample Student´s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001). n.d. indicates “not determined” (due to heartbeat arrest).
Ijms 20 00002 g002
Ijms 20 00002 g003 550
Figure 3. Diastolic and systolic intervals, fractional shortening and rhythmicity are modulated by peptide signalling in semi-intact Drosophila larvae. Individual effects of the tested peptides (1 × 10−7 M) on: (A) diastolic interval; (B) systolic interval; (C) fractional shortening; and (D) rhythmicity. Data are presented as mean values (± S.E.M.) of the relative changes in the respective parameters in relation to the individual control preparations (prior to peptide application). A minimum of ten animals per peptide were measured. Significance levels are indicated by asterisks (paired sample Student´s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001).
Figure 3. Diastolic and systolic intervals, fractional shortening and rhythmicity are modulated by peptide signalling in semi-intact Drosophila larvae. Individual effects of the tested peptides (1 × 10−7 M) on: (A) diastolic interval; (B) systolic interval; (C) fractional shortening; and (D) rhythmicity. Data are presented as mean values (± S.E.M.) of the relative changes in the respective parameters in relation to the individual control preparations (prior to peptide application). A minimum of ten animals per peptide were measured. Significance levels are indicated by asterisks (paired sample Student´s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001).
Ijms 20 00002 g003
Ijms 20 00002 g004 550
Figure 4. Representative M-modes of semi-intact larval Drosophila hearts incubated with distinct peptides (1 × 10−7 M). The movement of the heart walls over time (10 s) is depicted. Application of Corazonin, DH31, Proctolin, or Tachykinins 1, 3, or 5 has a cardioacceleratory effect. Application of Allatostatin A4 results in cardiac arrest. Upper panels represent control hearts (prior to peptide application); lower panels depict the same hearts 1 min after peptide application. Scale bars indicate 1 s.
Figure 4. Representative M-modes of semi-intact larval Drosophila hearts incubated with distinct peptides (1 × 10−7 M). The movement of the heart walls over time (10 s) is depicted. Application of Corazonin, DH31, Proctolin, or Tachykinins 1, 3, or 5 has a cardioacceleratory effect. Application of Allatostatin A4 results in cardiac arrest. Upper panels represent control hearts (prior to peptide application); lower panels depict the same hearts 1 min after peptide application. Scale bars indicate 1 s.
Ijms 20 00002 g004
Ijms 20 00002 g005 550
Figure 5. Knockdown of distinct peptide precursor proteins significantly affects heart function in intact Drosophila larvae. Depicted are the individual effects of peptide precursor protein knockdown on (A) heart rate and (B) rhythmicity. daughterless-Gal4 (da-Gal4) was used as a ubiquitous driver. Data are presented as mean values (± S.E.M.) of the relative changes in the respective parameters in relation to the depicted controls. At least ten animals per genotype were measured. Significance levels are indicated by asterisks (Student´s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001).
Figure 5. Knockdown of distinct peptide precursor proteins significantly affects heart function in intact Drosophila larvae. Depicted are the individual effects of peptide precursor protein knockdown on (A) heart rate and (B) rhythmicity. daughterless-Gal4 (da-Gal4) was used as a ubiquitous driver. Data are presented as mean values (± S.E.M.) of the relative changes in the respective parameters in relation to the depicted controls. At least ten animals per genotype were measured. Significance levels are indicated by asterisks (Student´s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001).
Ijms 20 00002 g005
Table
Table 1. Peptides used in this study and corresponding effects on distinct heart parameters in semi-intact larvae.
Table 1. Peptides used in this study and corresponding effects on distinct heart parameters in semi-intact larvae.
PeptideSequenceHeart RateDiastolic IntervalSystolic IntervalFractional ShorteningArrhythmicity Index
AKHQLTFSPDWa/////
AstA1VERYAFGLa///+/
AstA2LPVYNFGLa/-+//
AstA3SRPYSFGLa/////
AstA4TTRPQPFNFGLaΘΘΘΘΘ
CorazoninQTFQYSRGWTNa++--+//
DH31TVDFGLARGYSGTQEAKHRMGLAAANFAGGPa+++---//
DSK1FDDYGHMRFa/////
DSK2GGDDQFDDYGHMRFa/////
LeucokininNSVVLGKKQRFHSWGa///+/
ProctolinRYLPT+++---//+
sNPF11-11AQRSPSLRLRFa/////
sNPF14-11 sNPF212-19SPSLRLRFa/////
Tachykinin 1APTSSFIGMRa+++--//+
Tachykinin 2APLAFVGLRa/////
Tachykinin 3APTGFTGMRa+////
Tachykinin 4APVNSFVGMRa////++
Tachykinin 5APNGFLGMRa+++--///
Tachykinin 6AALSDSYDLRGKQQRFADFNSKFVAVRa/////
Listed are all peptides applied in this study along with their respective sequence and the effects on individual heart parameters (at 1 × 10−7 M). Nomenclature indicates significance of the observed effects (+ = increase, p < 0.05; ++ = increase, p < 0.01; +++ = increase, p < 0.001; - = decrease, p < 0.05; -- = decrease, p < 0.01; --- = decrease, p < 0.001; / = no significant effect; paired sample Student´s t-test). Θ indicates full arrest of heartbeat upon peptide application.
Table
Table 2. RNAi lines used in this study.
Table 2. RNAi lines used in this study.
Provided byCollectionIdentifierTarget Gene
VDRCKKVDRC-ID 103215CG13633; Allatostatin A
VDRCGDVDRC-ID 50295CG13094; Diuretic hormone 31
VDRCGDVDRC-ID 37763CG13094; Diuretic hormone 31
VDRCKKVDRC-ID 106876CG3302; Corazonin
VDRCKKVDRC-ID 102488CG7105; Proctolin
VDRCKKVDRC-ID 103662CG14734; Tachykinin
BDSCTRiPRRID:BDSC_25800CG14734; Tachykinin
BDSCTRiPRRID:BDSC_25866CG13633; Allatostatin A
BDSCTRiPRRID:BDSC_25999CG3302; Corazonin
BDSCTRiPRRID:BDSC_29570CG7105; Proctolin

Share and Cite

MDPI and ACS Style

Schiemann, R.; Lammers, K.; Janz, M.; Lohmann, J.; Paululat, A.; Meyer, H. Identification and In Vivo Characterisation of Cardioactive Peptides in Drosophila melanogaster. Int. J. Mol. Sci. 2019, 20, 2. https://doi.org/10.3390/ijms20010002

AMA Style

Schiemann R, Lammers K, Janz M, Lohmann J, Paululat A, Meyer H. Identification and In Vivo Characterisation of Cardioactive Peptides in Drosophila melanogaster. International Journal of Molecular Sciences. 2019; 20(1):2. https://doi.org/10.3390/ijms20010002

Chicago/Turabian Style

Schiemann, Ronja, Kay Lammers, Maren Janz, Jana Lohmann, Achim Paululat, and Heiko Meyer. 2019. "Identification and In Vivo Characterisation of Cardioactive Peptides in Drosophila melanogaster" International Journal of Molecular Sciences 20, no. 1: 2. https://doi.org/10.3390/ijms20010002

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop